DSP and Nitto Denko initiate Phase II schizophrenia studies

September 2012
PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p11
Market Research Report
The article reports on the start of Phase II studies by Dainippon Sumitomo Pharma (DSP) and Nitto Denko Corp. for a transdermal patch formulation of the atypical antipsychotic Lonasen for the treatment of schizophrenia. Results of Phase I studies are mentioned. General characteristics of a transdermal patch formulation include ability to maintain a stable drug concentration in the blood and less susceptibility to dietary effects.


Related Articles

  • Dainippon and Takeda announce EMA acceptance of MAA for schizophrenia drug.  // PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p17 

    The article reports on the European Medicines Agency (EMA) acceptance for review of the marketing authorization application (MAA) for schizophrenia drug received by Dainippon Sumitomo Pharma Co., Ltd. and Takeda Pharmaceutical Company Limited. The MAA for the antipsychotic medication lurasidone...

  • Intercept Pharma NASH Drug Disappoints In Japan. AMY REEVES // Investors Business Daily;10/28/2015, p00 

    The article reports that Intercept Pharmaceuticals, a biopharmaceutical company, is trading down on October 28, 2015 following the first Japanese trial of its fatty-liver-disease drug. It states that the trial was conducted by company's partner Dainippon Sumitomo Pharma, and the result was a...

  • Dainippon Sumitomo Pharma Reports that Latuda(r) (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that Dainippon Sumitomo Pharma Co. Ltd. (DSP) has released results from its two Phase 3 clinical trials. The trials were designed to evaluate the efficacy and safety of LATUDA in patients withbipolar I depression. Both the studies found that patients recieving LATUDA...

  • Dainippon Sumitomo's two Phase III bipolar disorder trials meet end points.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p25 

    The article reports on the results from two Phase III clinical trials designed to evaluate the safety and efficacy of LATUDA as monotherapy and adjunctive therapy, announced by Dainippon Sumitomo Pharma Co. Ltd. It states that LATUDA is not approved by the U.S. Food and Drug Administration (FDA)...

  • Antipsychotic Combination Therapy: Does It Make Sense? Marks, Robert // Behavioral Health Management;Nov/Dec2003, Vol. 23 Issue 6, pS3 

    Ponders on the effectiveness of antipsychotic combination therapy for the treatment of schizophrenia. Medications involved in the practice of such therapy; Practical indications that suggest the merit of such practice; Theoretical bases for combining antipsychotics and conducting clinical...

  • The CATIE and CUtLASS Studies in Schizophrenia. Naber, Dieter; Lambert, Martin // CNS Drugs;2009, Vol. 23 Issue 8, p649 

    Numerous double-blind studies have compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs), with most finding better efficacy and tolerability for SGAs. However, these 'efficacy trials' were generally short term and included only highly selected patients....

  • Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. Stauffer, Virginia; Ascher-Svanum, Haya; Lin Liu; Ball, Tamara; Conley, Robert // BMC Psychiatry;2009, Vol. 9, Special section p1 

    Background: How long an antipsychotic is effective in maintaining response is important in choosing the correct treatment for people with schizophrenia. This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone,...

  • Clinical trial participant's suicide raises ethical questions for IRBs.  // IRB Advisor;Aug2008, Vol. 8 Issue 8, p85 

    The article describes the ethical questions raised over the May 2004 suicide of a clinical trial participant. Twenty-seven-year-old Dan Markingson killed himself about six months into a clinical trial comparing antipsychotic medications used to treat schizophrenia. Mary Weiss alleged that her...

  • Åžizofrenide Kombinasyon Tedavileri. Altınyazar, Vesile; Yüksel, Nevzat // Klinik Psikofarmakoloji Bulteni;Dec2011, Vol. 21 Issue 4, p368 

    Use of multiple antipsychotic agents in patients with schizophrenia, especially in treatment resistant schizophrenia, is common practice in psychiatry, although most schizophrenia guidelines recommend monotherapy. There is limited evidence to support the combination of multiple antipsychotics in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics